Tulio Ortega, MD
Psychiatry · Rochester, NYNPI 1114013364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $268,120 of the $319,135 with a category attached, or 84.0%. 22 manufacturers reported payments, led by Alkermes, Inc. at 59.6% of the total. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 806 payments — averaging $395.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$190K
- AbbVie$77K
- E.r. Squibb & Sons, L.L.C.$27K
- Vanda Pharmaceuticals Inc.$21K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$865
- Teva Pharmaceuticals USA, Inc.$708
- plus $3K from 16 others
Across 80 payments — averaging $2158.35 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alkermes, Inc.$173K
What the payments were for
- Consulting fees$15,8555%
- Speaking & faculty fees$268,12084%
- Travel & lodging$17,5085%
- Food & beverage$17,3655%
- Education$2880%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 285 | $190,194 |
| AbbVie(2 entities) | 203 | $76,511 |
| E.r. Squibb & Sons, L.L.C. | 40 | $26,546 |
| Vanda Pharmaceuticals Inc. | 27 | $21,273 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $865 |
| Teva Pharmaceuticals USA, Inc. | 34 | $708 |
| Otsuka America Pharmaceutical, Inc. | 46 | $694 |
| Avanir Pharmaceuticals, Inc. | 24 | $413 |
| Johnson & Johnson | 16 | $319 |
| Lundbeck LLC | 14 | $309 |
| Neurocrine Biosciences, Inc. | 15 | $254 |
| Sunovion Pharmaceuticals Inc. | 22 | $236 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $211 |
| Axsome Therapeutics, Inc. | 9 | $186 |
| Supernus Pharmaceuticals, Inc. | 4 | $155 |
| Corium, LLC | 4 | $60 |
| Janssen Scientific Affairs, LLC | 1 | $50 |
| Bausch Health US, LLC | 2 | $42 |
| Merck | 2 | $40 |
| Neos Therapeutics, LP | 2 | $34 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Indivior Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$319,135 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 111 | $159,303 |
| Invega SustennaPaliperidone Palmitate | 32 | $116,654 |
| LybalviOlanzapine/Samidorphan Malate | 55 | $92,495 |
| Abilify MaintenaAripiprazole | 24 | $67,970 |
| NuedextaDextromethorphan Hbr/Quinidine | 21 | $31,773 |
| TrintellixVortioxetine Hydrobromide | 37 | $23,556 |
| Bupropion XlBupropion Hcl | 652 | $18,634 |
| Quetiapine Fumarate | 763 | $14,591 |
| Lurasidone Hcl | 23 | $12,931 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,296 |
| VyvanseLisdexamfetamine Dimesylate | 21 | $9,148 |
| Duloxetine Hcl | 369 | $8,749 |
| Aripiprazole | 240 | $8,621 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 172 | $6,930 |
| Clozapine | 65 | $6,170 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $76,511 | $159,303111 claims |
| Johnson & JohnsonInvega Sustenna | $319 | $116,65432 claims |
| Alkermes, Inc.Lybalvi | $190,194 | $92,49555 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $694 | $67,97024 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $211 | $32,70458 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $413 | $31,77321 claims |
| Axsome Therapeutics, Inc.Auvelity | $186 | $11,29611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Rochester
- Anton PorsteinssonRochester$295K
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.